Immatics’ (IMTX) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Immatics (NASDAQ:IMTX) in a research report sent to investors on Tuesday,Benzinga reports.

Immatics Price Performance

IMTX stock opened at $4.00 on Tuesday. Immatics has a 1-year low of $3.88 and a 1-year high of $13.77. The business has a 50 day simple moving average of $4.91 and a two-hundred day simple moving average of $7.31. The company has a market capitalization of $477.42 million, a price-to-earnings ratio of -6.06 and a beta of 0.83.

Immatics (NASDAQ:IMTX) last issued its earnings results on Thursday, March 27th. The company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.51. The firm had revenue of $15.67 million during the quarter, compared to analyst estimates of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. Sell-side analysts anticipate that Immatics will post -0.72 EPS for the current fiscal year.

Institutional Investors Weigh In On Immatics

A number of hedge funds have recently made changes to their positions in IMTX. Bank of America Corp DE grew its holdings in Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after buying an additional 2,231 shares in the last quarter. Virtus ETF Advisers LLC boosted its position in shares of Immatics by 34.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company’s stock valued at $68,000 after acquiring an additional 2,479 shares during the last quarter. Guggenheim Capital LLC bought a new position in shares of Immatics during the 4th quarter valued at approximately $101,000. Forefront Analytics LLC grew its holdings in shares of Immatics by 42.3% in the fourth quarter. Forefront Analytics LLC now owns 15,911 shares of the company’s stock valued at $113,000 after purchasing an additional 4,731 shares in the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc bought a new stake in Immatics in the third quarter worth $114,000. 64.41% of the stock is currently owned by hedge funds and other institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.